Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study

The role of low levels of HDV‐RNA during and after interferon therapy of hepatitis D is unknown. We re‐analysed HDV RNA in 372 samples collected in the HIDIT‐2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previousl...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2021-02, Vol.41 (2), p.295-299
Main Authors: Bremer, Birgit, Anastasiou, Olympia E., Hardtke, Svenja, Caruntu, Florin Alexandru, Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Radu, Monica, Idilman, Ramazan, Manns, Michael P., Cornberg, Markus, Yurdaydin, Cihan, Wedemeyer, Heiner
Format: Article
Language:English
Subjects:
Assaying
HDV
Hepatitis
Hepatitis D
Infectious diseases
Interferon
PCR
relapse
residual viraemia
Ribonucleic acid
RNA
Viremia
α-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The role of low levels of HDV‐RNA during and after interferon therapy of hepatitis D is unknown. We re‐analysed HDV RNA in 372 samples collected in the HIDIT‐2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in‐house assay (IA). We detected HDV‐RNA in one‐third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post‐treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post‐treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14740